Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

ElixaMD vs NuvaHealth

ElixaMD
Graded #251

Lower grade

vs+10.5
NuvaHealth
Graded #65

Higher grade

The verdict

NuvaHealth takes it — 74.2/100 to 63.7/100.

NuvaHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. NuvaHealth (nuvahealth.org) is a LegitScript-certified compounded GLP-1 telehealth platform offering compounded semaglutide starting at $159 first-month and compounded tirzepatide starting at $259 first-month.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueNuvaHealth +25
51
76
Dose & formulationNuvaHealth +36
52
88
Clinical oversightElixaMD +10
92
82
Labs & monitoringElixaMD +10
63
53
FulfillmentElixaMD +2
76
74
Contract termsNuvaHealth +10
45
55
ElixaMD · left barNuvaHealth · right bar

The numbers

MetricElixaMDNuvaHealth
WeighScore63.7/10074.2/100
GradeCC
Scorecard rank#251#65
Semaglutide$179/mo (starting dose, first-month rate, compounded)$139/mo (first-month rate, compounded)
TirzepatideNot disclosed$229/mo (first-month rate, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualInjection onlyYes
ElixaMD

Graded #251 · C

Strengths

  • Compounded semaglutide from $179 first month with free shipping, no membership, no contract, and no insurance required
  • Genuinely all-inclusive: 1:1 physician guidance, free dietician visits and care coaching, 24/7 support, and an all-in-one patient portal
  • Names its compounding pharmacies (RedRock Pharmacy, Beaker Pharmacy) — more transparent than most compounded sellers
  • HSA/FSA eligible; full legal suite (Terms, Privacy, Privacy Practices, Refund, Medical Consent, California Bill of Rights)

Where it loses points

  • $179 is a first-month/intro price — ongoing monthly cost is higher (tiers to ~$249-$299)
  • Compounded semaglutide is not FDA-approved (the site discloses this) — not brand Wegovy or Ozempic
  • Appears to offer compounded semaglutide only — tirzepatide is not advertised
  • Displays a generic LegitScript Certified badge but no verifiable seal/listing; state-availability list not published
NuvaHealth

Graded #65 · C

Strengths

  • LegitScript Certified seal displayed on the marketing site (the standard third-party telehealth/pharmacy accreditation)
  • Free and fast delivery + 24/7 patient support disclosed on the home page
  • Newark, DE address suggests a US-incorporated entity (vs offshore)
  • $139 first-month price for compounded semaglutide injection is among the cheapest in the US compounded telehealth market
  • $229 first-month price for compounded tirzepatide injection sits in the lower-median range

Where it loses points

  • Standard ongoing monthly price NOT publicly disclosed (gated behind checkout) — patients should ask for the maintenance-dose price before committing
  • Specific legal entity name + state of incorporation NOT publicly disclosed on the home page — material YMYL transparency gap
  • Pharmacy partners NOT publicly named — material YMYL transparency gap
  • Per-state availability NOT enumerated; verify your state ships before purchase
  • Lab work + coaching support NOT publicly disclosed

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard